Bullish indicating open at $55-$60, IPO prices at $37
Colleen Tupper, the Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. The transactions, which took place on March 20 and 21, were conducted under a Rule 10b5-1 trading plan adopted on August 14, 2024. The company, currently valued at $961 million, has maintained impressive gross profit margins of 87% and received a "GREAT" financial health rating according to InvestingPro analysis.
In the first transaction on March 20, Tupper sold 1,206 shares at a weighted average price of approximately $30.00 per share, netting her about $36,183. The following day, she sold an additional 6,396 shares at an average price of $30.03 per share, generating approximately $192,067. In total, these sales amounted to $228,250. Notably, InvestingPro data shows management has been actively buying back shares, with 7 additional exclusive insights available to subscribers.
Following these transactions, Tupper retains direct ownership of 156,667 shares of Collegium Pharmaceutical. The sales were executed at prices ranging from $30.00 to $30.50. The stock, which has seen a 4.89% gain year-to-date, is currently trading near its InvestingPro Fair Value. Get comprehensive insights with the Pro Research Report, available along with detailed financial analysis for 1,400+ US stocks on InvestingPro.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, which exceeded analyst expectations. The company achieved an earnings per share (EPS) of $1.75, surpassing the forecast of $1.66, and reported revenue of $181.9 million, exceeding the anticipated $179.48 million. This performance was driven by strong demand for its ADHD medication, Jornay, and its pain management products, BELBUCA and Xtampza ER. Additionally, Collegium announced significant changes to its Board of Directors and executive team, with Gino Santini set to become the new Chairman of the Board. The company also appointed David Dieter, Jane Gonnerman, and Dean J. Patras to key executive positions, aiming to bolster its leadership for future growth. Furthermore, H.C. Wainwright maintained a Buy rating on Collegium, with a price target of $50, citing confidence in the company’s valuation despite potential generic competition risks. These developments reflect Collegium’s strategic focus on governance, operational excellence, and expanding its portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.